Document:

EX-10.28

 Exhibit 10.28 

CONFIDENTIAL TREATMENT REQUESTED 

COOPERATION AGREEMENT 
 This
AGREEMENT is entered into as of date of signature hereof by and between: 
 WuXI AppTec, Inc., having a mailing address of 4751 League
Island Blvd., Philadelphia, PA 19112, USA (WUXI APPTEC) and, 
 REGENXBIO Inc., having a principal place of business at 9712 Medical Center
Drive, Suite 100, Rockville, MD 20850 (REGENX). 
 Hereinafter individually referred to as “Party” and collectively as “Parties”.

 WHEREAS, WUXI APPTEC is a service laboratory which offers contract testing, process development, and regulatory compliant manufacturing services
for biopharmaceuticals, medical devices, cellular therapeutics, gene therapies, and tissue-based products; and 
 WHEREAS, REGENX is an
organization that drives the development of NAV® gene therapies through its own development, manufacturing and commercialization of NAV gene therapy treatments for a number of diseases
including lysosomal storage disorders and ocular diseases and the licensing of NAV Technology to ther companies,. 
 WHEREAS, WUXI APPTEC and
REGENX intend to enter into a collaboration that will take advantage of the complementary strengths of both companies within the AAV gene therapy area; and 

WHEREAS, the purpose of the intended collaboration is to offer REGENX-established NAV gene therapy programs, and REGENX licensees (collectively,
Customers) at their choice, specialized contract services for the efficient progression of these gene therapy programs through the various stages of preclinical and clinical development and manufacturing to the benefit of both companies and
Customers; and 
 WHEREAS, the Parties do not intend or wish to restrict or control in any way the decision of Customers to utilize either
REGENX or WUXI APPTEC. 
 Now Therefore, the parties hereby agree as follows: 

Article 1         Definitions 
  

	1.1	“Confidential Information” means (i) the terms of this Agreement and (ii) any and all information relating to the subject matter of this Agreement, including but not limited to know-how,
technical information, research, marketing, strategic or other information that is disclosed in writing, visually, orally or in electronic medium by the Providing Party (as defined in Article 3) or its Affiliates to the Receiving Party (as defined
in Article 3) or its Affiliates, whether prior to or after signature of this Agreement, in the course of the Parties’ evaluation, negotiation of or performance under this Agreement. 

 

	1.2	“Contract Services” shall mean (i) contract manufacturing services for NAV gene therapy products with or without cell line and/or process development and scale-up activities, and (ii) testing
services including but not limited to cell bank characterization, virus characterization, lot release testing, toxicology and biodistribution studies, molecular biology studies, analytical characterization, and custom testing studies.

  
 page 1 / 6 

 CONFIDENTIAL TREATMENT REQUESTED 

 
 Article 2         Object of the Agreement

  

	2.1	Cooperative Partnership 

 Regulatory compliant manufacturing and testing services are
required to enable the efficient advancement of REGENX-established NAV gene therapy programs, requiring the transfer ofspecific technical and process information to a contract development and manufacturing organization. Once transferred, efficiency
is gained in the application of this information to subsequent products utilizing the REGENX technology for the development of REGENX products or those of REGENX licensees. Moreover, the ability to provide process development, manufacturing and
testing facilities of adequate capacity and meeting compliance standards appropriate for supply of late stage clinical and commercial materials provides an incentive for adoption of the REGENX technology and can advance the programs of REGENX
licensees. 
 WUXI APPTEC is currently providing specialized process development, testing and compliant manufacturing services for an array
of biological and cellular therapy products and is expanding facilities and capabilities to provide services to support the clinical and commercial supply of gene therapy products. Establishing familiarity with the REGENX process and analytical
technology, and receiving access to future technology enhancements may provide an advantage to WUXI APPTEC in providing commercial services for the programs of REGENX and its licensees. 

REGENX and WUXI APPTEC acknowledge each other as cooperative partners with the goal of establishing WUXI APPTEC as the preferred process
development, testing and manufacturing service provider for REGENX and REGENX licensees. Through this cooperative partnering relationship WUXI APPTEC will work with REGENX to establish standard processes applicable to the REGENX technology platform
which may be applied for the development, testing and manufacture of REGENX products or those of REGENX licensees. In partnering, the parties intend to enhance the contract service business opportunities for WUXI APPTEC and to enhance the business
opportunities of REGENX (1) in the efficient development of its gene therapy programs, (2) in the adoption of REGENX manufacturing technology, and (3) through the provision of a knowledgeable and compliant manufacturing and testing
resource for its licensees. 
  

	2.2	Joint Steering Committee 

 REGENX and WUXI APPTEC will develop a Joint Steering Committee
consisting of **** in order to discuss and address issues relating to the Cooperation Agreement. **** shall be selected by REGENX and **** shall be selected by WUXI APPTEC. The Joint Steering Committee shall meet **** or otherwise as agreed-to by
the members, either in person or by phone. 
  

	2.3	Technology transfer and manufacturing resources 

 REGENX shall provide process
development, analytical methods and information and training necessary for WUXI APPTEC to reasonably provide process development, testing and manufacturing services for the production of REGENX products. WUXI APPTEC will establish these services
consistent with its manufacturing, testing and quality systems in order to provide regulatory compliant services to REGENX and REGENX licensees. For the avoidance of doubt, WUXI APPTEC shall provide services incorporating REGENX-provided
information, methods and training only to REGENX and REGENX licensees. 
  

	2.4	Ongoing support and technology advancements 

 REGENX will provide reasonable direct
support and the assistance of its technical, scientific staff and advisors if requested, to advise WUXI APPTEC on the effective application of the technology or to troubleshoot or resolve technical issues to the best of its abilities which may arise
in the application of REGENX technology on behalf of WUXI APPTEC’s support of REGENX and its licensees. WUXI APPTEC and REGENX will work cooperatively to incorporate reasonable advancements in manufacturing processes, analytical testing or
quality control paradigms which may provide for increased process efficiency, safety, quality or regulatory compliance. 

  
 page 2 / 6 

****CERTAIN INFORMATION HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH
RESPECT TO THE OMITTED PORTIONS. 

 CONFIDENTIAL TREATMENT REQUESTED 

 
  

	2.5	Access to process development, testing and manufacturing 

 WUXI APPTEC shall provide
access to process development, testing and manufacturing resources for REGENX and REGENX licensee’s **** WUXI APPTEC will work with REGENX to provide preferred scheduling and performance of services supporting REGENX gene therapy programs and
those of REGENX licensees. ****. 
  

	2.6	Recommendation and Use of WUXI APPTEC by REGENX for Contract Services 

 REGENX shall
recommend WUXI APPTEC as its preferred provider of process development, testing and manufacturing services to Customers provided that WUXI APPTEC maintains acceptable quality standards and conformance with generally recognized industry standards.
****. 
  

	2.7	Ethical practices 

 The Parties agrees that they will not engage in any deceptive,
misleading or unethical practices that are or might be detrimental to the other Party, any Customer or the general public. 
  

	2.8	Promotion of technology and services 

 WUXI APPTEC and REGENX shall jointly agree upon
mechanisms to promote the availability of the specialized services relating to the REGENX technology, the potential advantages of the technology, and the availability of process development, testing and manufacturing services. The Parties agree that
any promotional materials or reference to the other Parties’ services will be with the prior review and expressed written approval of the other Party. During the term of the Agreement, WUXI APPTEC will not enter into a similar Cooperation
Agreement for manufacturing services with other companies developing technology platforms for AAV-mediated gene therapies. ****. 
 Article 3
         Confidentiality 
  

	3.1	General 

 Parties undertake to hold in strict confidence all Confidential Information
which has been or will be made available to either Party (hereinafter referred to as the “Receiving Party”) by the other Party (hereinafter referred to as the Providing Party”) and accordingly (i) not to disclose such
Confidential Information to third parties without the prior written consent of the Providing Party, except to such **** to disclose such Confidential Information for the purpose of this Agreement, and (ii) not to use such Confidential
Information for any purpose other than the cooperation and the performance of this Cooperation Agreement as agreed herein. 
  

	3.2	Special Disclosure 

 If Confidential Information is disclosed by a Party or its
Affiliates other than in written or electronic form, then the Receiving Party’s obligations of confidentiality and non-use shall only apply if the Confidential Information is indicated upon disclosure as being confidential and is then
summarized electronically or in writing and provided to the other Party within **** after initial disclosure. 

  
 page 3 / 6 

****CERTAIN INFORMATION HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH
RESPECT TO THE OMITTED PORTIONS. 

 CONFIDENTIAL TREATMENT REQUESTED 

 

	3.3	Permitted Disclosure 

 Before any Confidential Information is passed on to **** or to
third parties after written consent of the Providing Party in accordance with Article 3.1, the Receiving Party undertakes to impose all obligations on said **** or third parties as imposed on Receiving Party under this Agreement. 

 

	3.4	Exceptions 

 The obligations contained in this Article 3 shall not apply to such
Confidential Information which (i) is in the possession of the Receiving Party prior to disclosure or which becomes known to the 

Receiving Party without having been furnished, directly or indirectly, by the Providing Party or any of its Affiliated Companies, or
(ii) was public knowledge at the time of disclosure or which becomes public knowledge after disclosure in circumstances which are not the fault or negligence of the Receiving Party, or (iii) can be shown by written documentation to have
been made known to a Party or its Affiliates from another source free from any obligation of confidentiality, or (iv) was not obtained either directly or indirectly from the other Party or its Affiliates. 

 

	3.5	Disclosure of Confidential Information 

 In the event that a Party is required by law,
regulation, rule, act or order of any governmental authority or agency to disclose Confidential Information of the other Party, it shall be entitled to do so provided that it shall first notify the other Party forthwith of any such required
disclosure and limit such disclosure as far as is possible under applicable law. Such disclosure shall, however, not relieve either Party of its other obligations contained herein. 

 

	3.6	Return of Confidential Information 

 The Receiving Party shall upon expiry or termination
of this Agreement return to the Providing Party all Confidential Information and shall not retain any copies thereof, except for one copy, which might be retained by either party for documentation purposes. 

 

	3.7	Term of Confidentiality 

 This Article 3 shall remain in force during the period of this
Agreement and for a further period of **** after the termination or expiration thereof. 
 Article 4
        Public Disclosure 
 Except to the extent allowed under Article 2 or required by law,
neither Party will make any public announcement, statement or communication with respect to the existence and/or activities under this Cooperation Agreement without the prior written consent of the other Party. 

Article 5         No financial obligation 

Neither Party shall owe any payment to the other Party due to activities undertaken under this Cooperation Agreement. ****. 

Article 6         Term and Termination 

 

	6.1	Term 

 This Agreement shall enter into force on the date of signature hereof by both
Parties and shall continue until and unless terminated in accordance with this Agreement. 

	6.2	Termination 

 Either Party may terminate this Agreement: 

  
 page 4 / 6 

****CERTAIN INFORMATION HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH
RESPECT TO THE OMITTED PORTIONS. 

 CONFIDENTIAL TREATMENT REQUESTED 

 
 a) if the other commits a material breach of the Agreement which in the
case of a breach capable of remedy is not remedied to the reasonable satisfaction of the non-breaching Party within **** of the receipt by the other of written notice identifying the breach and requiring its remedy; or 

b) if the other party files a petition of any type as to its bankruptcy, is declared bankrupt, becomes insolvent, makes an assignment for the
benefit of creditors, goes into liquidation or receivership, otherwise loses legal control of its business or ceases to carry on its business. 
  

	6.3	Elective Termination 

 Either party shall be entitled to terminate this Agreement at any
time by giving **** written notice. 
 Article 7         General Provisions 

 

	7.1	Force Majeure 

 Neither Party shall be liable for delay or failure to perform hereunder
due to any contingency beyond its control, including, but not limited to acts of God, fires, floods, wars, civil wars or sabotage, provided, such Party promptly gives to the other Party hereto written notice claiming force majeure and uses its best
efforts to eliminate the effect of such force majeure, insofar as is possible and with all reasonable dispatch. If the period of delay or failure with respect to either Party should extend for **** or more, consecutively or cumulatively, in any
one-year period commencing on the effective date of this Agreement, as provided above, then either Party shall in its discretion have the right to terminate this Agreement forthwith upon written notice at any time after expiration of said ****
period. 
  

	7.2	No Waiver 

 No failure or delay on the part of either WUXI APPTEC or REGENX to exercise
or enforce any rights conferred on it by the Agreement shall be construed or operate as a waiver thereof nor shall any single or partial exercise of any right, power or privilege or further exercise thereof operate so as to bar the exercise or
enforcement thereof at any time or times thereafter. 
  

	7.3	Independent Contractor 

 In the performance of this Agreement each Party shall be an
independent contractor, and therefore, no Party shall be entitled to any benefits applicable to any employee of the other Party. No Party is authorized to act as an agent for the other Party for any purpose, and no Party shall enter into any
contract, warranty or representation as to any matter on behalf of the other Party. In all cases unless otherwise modified by written agreement of both Parties this Agreement is not creating or inferring a Joint Venture or a legal Partnership
between WUXI APPTEC and REGENX. 
  

	7.4	Written Form 

 No amendments, changes, modifications or alterations of the terms and
conditions of this Cooperation Agreement shall be binding upon either Party, unless in writing and signed by both Parties. This applies also to the amendment, change etc. of the requirement of written form under this Section. 

 

	7.5	Entire Understanding 

 This Agreement contains the entire understanding between the
Parties and supersedes any and all prior agreements, understandings and arrangements, whether written or oral between the Parties. 
  

	7.6	Severability 

 The illegality or invalidity of any provision (or any part thereof) of
this Cooperation Agreement shall not affect the legality, validity or enforceability of the remainder of its provisions or the other parts of such provision as the case may be. 

  
 page 5 / 6 

****CERTAIN INFORMATION HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH
RESPECT TO THE OMITTED PORTIONS. 

 CONFIDENTIAL TREATMENT REQUESTED 

 
 Article 8         Mediation, Arbitration, and
Governing Law 
  

	8.1	Applicable Law 

 This Cooperation Agreement shall be governed by and construed under the
laws of the Commonwealth of Pennsylvania without regard to the doctrine of conflict of laws. 
  

	8.2	Mediation 

 In the event of any dispute, controversy or claim arising out of or relating
to this Agreement, or the breach, termination or invalidity thereof, each party shall by written notice to the other have the right to have such dispute referred to the senior management of WUXI APPTEC and REGENX for attempted resolution by good
faith negotiations within **** after such notice is received. If such senior management are unable to resolve such dispute within such **** **** period, either party may invoke the provisions of Section 8.3. Any settlement reached by the
parties under this Section 8.2 shall not be binding until reduced to writing and signed by the above-specified management of WUXI APPTEC and REGENX. When reduced to writing, such agreement shall supersede all other agreements, written or oral,
to the extent such agreements specifically pertain to the matters so settled. 
  

	8.3	Arbitration 

 In the event of the failure to reach a resolution pursuant to
Section 8.2, any dispute, controversy or claim arising out of or relating to this Agreement, or the breach, termination or invalidity thereof, shall be finally settled by binding arbitration in accordance with the complex rules of the
Commercial Arbitration Rules of the American Arbitration Association in effect on the date of this Agreement by a single arbitrator who shall be experienced in the Biopharmaceutical industry and who shall be appointed in accordance with such rules.
The place of arbitration shall be Philadelphia, Pennsylvania, and the parties shall **** filing fees, arbitrator fees or other costs of such proceedings, **** attorney’s fees, and other out-of-pocket arbitration expenses, unless the arbitrator
decides otherwise. 
 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by their respective duly
authorized representatives as of the date of the last signature below. 
  

									
	WuXi AppTec Inc.				REGENXBIO Inc.
					
	By:		 /s/ W. Alan Moore
				By:		 /s/ Kenneth Mills

	Name :		W. Alan Moore				Name:		Kenneth Mills
	Title:		Vice President, Cell Manufacturing				Title:		President & CEO
	Date:		May 28, 2015				Date:		May 27, 2015

  
 page 6 / 6 

****CERTAIN INFORMATION HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH
RESPECT TO THE OMITTED PORTIONS.EX-10.29

 Exhibit 10.29 

REGENXBIO INC. 

MANAGEMENT CASH INCENTIVE PLAN 

(AS ADOPTED EFFECTIVE SEPTEMBER     , 2015) 

 TABLE OF CONTENTS 

 

							
	 	 	 	  	Page	 
			
	ARTICLE 1.	 	BACKGROUND AND PURPOSE	  	 	1	  
	 1.1
	 	Effective Date	  	 	1	  
	 1.2
	 	Purpose of the Plan	  	 	1	  
			
	ARTICLE 2.	 	DEFINITIONS	  	 	1	  
			
	ARTICLE 3.	 	SELECTION OF PARTICIPANTS AND DETERMINATION OF AWARDS	  	 	3	  
	 3.1
	 	Selection of Participants	  	 	3	  
	 3.2
	 	Determination of Performance Goals	  	 	3	  
	 3.3
	 	Determination of Target Awards	  	 	3	  
	 3.4
	 	Determination of Payout Formula or Formulae	  	 	3	  
	 3.5
	 	Determination of Actual Awards	  	 	3	  
	 3.6
	 	Adjustments	  	 	4	  
			
	ARTICLE 4.	 	PAYMENT OF AWARDS	  	 	4	  
	 4.1
	 	Right to Receive Payment	  	 	4	  
	 4.2
	 	Timing of Payment	  	 	4	  
	 4.3
	 	Form of Payment	  	 	4	  
	 4.4
	 	Payment in the Event of Death	  	 	4	  
			
	ARTICLE 5.	 	ADMINISTRATION	  	 	4	  
	 5.1
	 	Committee Authority	  	 	4	  
	 5.2
	 	Decisions Binding	  	 	5	  
	 5.3
	 	Delegation by the Committee	  	 	5	  
			
	ARTICLE 6.	 	GENERAL PROVISIONS	  	 	5	  
	 6.1
	 	Tax Withholding	  	 	5	  
	 6.2
	 	No Effect on Employment	  	 	5	  
	 6.3
	 	No Effect on Other Benefits	  	 	5	  
	 6.4
	 	Successors	  	 	5	  
	 6.5
	 	Nontransferability of Awards	  	 	5	  
			
	ARTICLE 7.	 	DURATION, AMENDMENT AND TERMINATION	  	 	5	  
	 7.1
	 	Duration of the Plan	  	 	5	  
	 7.2
	 	Amendment, Suspension or Termination	  	 	6	  
			
	ARTICLE 8.	 	LEGAL CONSTRUCTION	  	 	6	  
	 8.1
	 	Severability	  	 	6	  
	 8.2
	 	Requirements of Law	  	 	6	  
	 8.3
	 	Governing Law	  	 	6	  
	 8.4
	 	Captions	  	 	6	  
		
	Appendix A Performance Metrics	  	 	7	  

  
 i 

 REGENXBIO INC. 

MANAGEMENT CASH INCENTIVE PLAN 

ARTICLE 1. BACKGROUND AND PURPOSE 

1.1 Effective Date. The Plan was adopted by the Committee on the date set forth above, became effective immediately and is not subject
to approval by the Company’s stockholders. 
 1.2 Purpose of the Plan. The Plan is intended to motivate Participants to
achieve excellent short- and long-term financial performance for the Company and its business units. The Plan provides Participants with the opportunity to earn cash incentive awards for the achievement of goals relating to the performance of the
Company. 
 ARTICLE 2. DEFINITIONS 

The following words and phrases shall have the following meanings, unless a different meaning is plainly required by the context: 

2.1 “Actual Award” means, as to any Performance Period, the actual award (if any) payable to a Participant for the
Performance Period. Each Actual Award is determined by the Payout Formula for the Performance Period, subject to the Committee’s authority under Section 3.5 to increase, eliminate or reduce the award otherwise indicated by the Payout
Formula. 
 2.2 “Affiliate” means any corporation or other entity (including, without limitation, partnerships and joint
ventures) controlled by the Company. 
 2.3 “Base Salary” means, as to any Performance Period, the
Participant’s earned salary during the Performance Period. Base Salary shall be calculated before both (a) deductions for taxes or benefits and (b) deferrals of compensation pursuant to Company-sponsored plans or Affiliate-sponsored
plans. 
 2.4 “Board” means the Company’s Board of Directors. 

2.5 “Committee” means the Compensation Committee of the Board. 

2.6 “Company” means REGENXBIO Inc., a Delaware corporation, or any successor thereto. 

2.7 “Disability” means a permanent disability, as determined for purposes of the principal long-term disability insurance
plan maintained by the Company for the benefit of the Participant. If there is no such plan, Disability shall be determined in accordance with a policy established by the Committee. 

 2.8 “Employee” means any employee of the Company or of an Affiliate, whether
such employee is so employed when the Plan is adopted or becomes so employed after the adoption of the Plan. 
 2.9 “Fiscal
Quarter” means a fiscal quarter within a Fiscal Year of the Company. 
 2.10 “Fiscal Year” means the
fiscal year of the Company. 
 2.11 “Participant” means, as to any Performance Period, an Employee who has been selected
for participation in the Plan for that Performance Period pursuant to Section 3.1. 
 2.12 “Payout Formula”
means, as to any Performance Period, the formula or payout matrix established by the Committee pursuant to Section 3.4 in order to determine the Actual Awards (if any) to be paid to Participants. The formula or matrix may differ from
Participant to Participant. 
 2.13 “Performance Period” means a Fiscal Year, or any longer or shorter period
determined by the Committee. 
 2.14 “Performance Goals” means the goal(s) determined by the Committee to be
applicable to a Participant for a Target Award for a Performance Period. As determined by the Committee, the Performance Goal(s) may provide for a targeted level or levels of achievement using the performance criteria specified by the Committee.
Such criteria shall be based on one or more of the performance metrics set forth in Appendix A attached to the Plan. 
 2.15
“Plan” means this REGENXBIO Inc. Management Cash Incentive Plan, as set forth in this instrument and as hereafter amended from time to time. 

2.16 “Progress Payment” means a portion of the Target Award or Actual Award determined in accordance with
Section 3.5 that has been earned by the Participant as of the end of the Progress Period, based on achievement of the applicable Performance Goals, and that may be paid to the Participant during the Performance Period. 

2.17 “Progress Period” means a period shorter than and within the Performance Period for which a Progress Payment may
be made. 
 2.18 “Retirement” means, with respect to any Participant, a Termination of Employment occurring in accordance
with a policy or policies established by the Committee from time to time. 
 2.19 “Target Award” means the target
award payable under the Plan to a Participant for the Performance Period or Progress Period, as applicable, expressed as a percentage of his or her Base Salary or a specific dollar amount, as determined by the Committee in accordance with
Section 3.3. 

  
 2 

 2.20 “Termination of Employment” means a cessation of the employee-employer
relationship between an Employee and the Company or an Affiliate for any reason, including (without limitation) a termination by resignation, discharge, death, Disability, Retirement or the disaffiliation of an Affiliate, but excluding a transfer
from the Company to an Affiliate or between Affiliates. 
 ARTICLE 3. SELECTION OF PARTICIPANTS AND DETERMINATION OF AWARDS 

3.1 Selection of Participants. The Committee shall select the Employees who shall be Participants for any Performance Period. The
Committee also may designate as Participants one or more individuals (by name or position) who are expected to become Employees during a Performance Period. Participation in the Plan is in the sole discretion of the Committee and shall be determined
Performance Period by Performance Period. Accordingly, an Employee who is a Participant for a given Performance Period is in no way assured of being selected for participation in any subsequent Performance Period. 

3.2 Determination of Performance Goals. The Committee shall establish the Performance Goals for each Participant for the Performance
Period. Such Performance Goals shall be set forth in writing and shall be based on one or more of the performance metrics set forth in Appendix A attached to the Plan. Any criteria used may be measured (a) in absolute terms, (b) in
relative terms, including (without limitation) the passage of time and/or against other companies or metrics, (c) on a per-share basis, (d) against the performance of the Company as a whole or against particular segments or products of the
Company and/or (e) on a pre-tax or after-tax basis. Any Performance Goal may be measured on a basis other than generally accepted accounting principles. 

3.3 Determination of Target Awards. The Committee shall establish a Target Award for each Participant for each Performance Period. Such
Target Award shall be set forth in writing. 
 3.4 Determination of Payout Formula or Formulae. The Committee shall establish a
Payout Formula or Formulae for purposes of determining the Actual Award (if any) payable to each Participant. Each Payout Formula shall (a) be in writing, (b) be based on a comparison of actual performance to the Performance Goals,
(c) provide for the payment of a Participant’s Target Award if the Performance Goals for the Performance Period are achieved at the predetermined level and (d) provide for the payment of an Actual Award greater than or less than the
Participant’s Target Award, depending upon the extent to which actual performance exceeds or falls below the Performance Goals. 

3.5 Determination of Actual Awards. After the end of each Performance Period or, to the extent that Progress Payments will be made,
after the end of each Progress Period, the Committee shall certify the extent to which the Performance Goals applicable to each Participant for the Performance Period or Progress Period, as applicable, were achieved or exceeded, as determined by the
Committee. The Actual Award for each Participant shall be determined by applying the Payout Formula to the level of actual performance that has been certified by the Committee. Any contrary provision of the Plan notwithstanding, the Committee

  
 3 

 
may (a) reduce or eliminate the Actual Award that otherwise would be payable under the Payout Formula or (b) determine whether or not any Participant will receive an Actual Award or
Progress Payment in the event that the Participant incurs a Termination of Employment before such Actual Award or Progress Payment is to be paid pursuant to Section 4.2. 

3.6 Adjustments. The Committee may adjust the results under any Performance Goal to exclude any of the following events that occurs
during a Performance Period: (a) asset write-downs, (b) litigation, claims, judgments or settlements, (c) the effect of changes in tax law, accounting principles or other such laws or provisions affecting reported results,
(d) accruals for reorganization and restructuring programs, (e) mergers or acquisitions and (f) any other extraordinary, unusual or non-recurring items. 

ARTICLE 4. PAYMENT OF AWARDS 

4.1 Right to Receive Payment. Each Actual Award or Progress Payment that may become payable under the Plan shall be paid solely from the
general assets of the Company or the Affiliate that employs the Participant (as the case may be), as determined by the Company. No amounts awarded or accrued under the Plan shall be funded, set aside or otherwise segregated prior to payment. The
obligation to pay Actual Awards or Progress Payments under the Plan shall at all times be an unfunded and unsecured obligation of the Company. Participants shall have the status of general creditors of the Company or the Affiliate that employs the
Participant. 
 4.2 Timing of Payment. Subject to Section 3.5, payment of each Actual Award or Progress Payment shall be made as
soon as administratively practicable, but in no event later than two and one-half months after the end of the applicable Performance Period or Progress Period, as the case may be. 

4.3 Form of Payment. Each Actual Award or Progress Payment shall be paid in cash (or its equivalent) in a single lump sum. 

4.4 Payment in the Event of Death. If a Participant dies before receiving an Actual Award or Progress Payment (determined under
Section 3.5) that was scheduled to be paid before his or her death for a prior Performance Period or Progress Period, then the Actual Award or Progress Payment shall be paid to the Participant’s designated beneficiary or, if no beneficiary
has been designated, to the administrator or representative of his or her estate. Any beneficiary designation or revocation of a prior designation shall be effective only if it is in writing, signed by the Participant and received by the Company
prior to the Participant’s death. 
 ARTICLE 5. ADMINISTRATION 

5.1 Committee Authority. The Plan shall be administered by the Committee, subject to Section 5.3. The Committee shall have all
powers and discretion necessary or appropriate to administer the Plan and to control its operation, including (without limitation) the power to (a) determine which Employees shall be granted awards, (b) prescribe the terms and conditions
of the awards, (c) interpret the Plan, (d) adopt such procedures and sub-plans as are necessary or appropriate to permit participation in the Plan by Employees who are foreign nationals or employed outside of the United States,
(e) adopt rules for the administration, interpretation and application of the Plan and (f) interpret, amend or revoke any such rules. 

  
 4 

 5.2 Decisions Binding. All determinations and decisions made by the Committee, the Board
or any delegate of the Committee pursuant to the provisions of the Plan shall be final, conclusive and binding on all persons and shall be given the maximum deference permitted by law. 

5.3 Delegation by the Committee. The Committee, on such terms and conditions as it may provide, may delegate all or part of its
authority and powers under the Plan to one or more directors and/or employees of the Company. 
 ARTICLE 6. GENERAL PROVISIONS 

6.1 Tax Withholding. The Company or an Affiliate, as applicable, shall withhold all required taxes from an Actual Award or Progress
Payment, including any federal, state, local or other taxes. 
 6.2 No Effect on Employment. Nothing in the Plan shall interfere with
or limit in any way the right of the Company or an Affiliate, as applicable, to terminate any Participant’s employment or service at any time, with or without cause. Employment with the Company and its Affiliates is on an at-will basis only.
The Company expressly reserves the right, which may be exercised at any time and without regard to when during or after a Performance Period such exercise occurs, to terminate any individual’s employment with or without cause, and to treat him
or her without regard to the effect that such treatment might have upon him or her as a Participant. 
 6.3 No Effect on Other
Benefits. Except as expressly set forth in a Participant’s employment agreement with the Company, any Actual Awards or Progress Payments under the Plan shall not be considered for the purpose of calculating any other benefits to which such
Participant may be entitled, including (a) any termination, severance, redundancy or end-of-service payments, (b) other bonuses or long-service awards, (c) overtime premiums, (d) pension or retirement benefits or (e) future
Base Pay or any other payment to be made by the Company to such Participant. 
 6.4 Successors. All obligations of the Company and
any Affiliate under the Plan, with respect to awards granted hereunder, shall be binding on any successor to the Company and/or such Affiliate, whether the existence of such successor is the result of a merger, consolidation, direct or indirect
purchase of all or substantially all of the business or assets of the Company or such Affiliate, or any similar transaction. 
 6.5
Nontransferability of Awards. No award granted under the Plan shall be sold, transferred, pledged, assigned or otherwise alienated or hypothecated, other than by will, by the laws of descent and distribution or to the limited
extent provided in Section 4.4. All rights with respect to an award granted to a Participant shall be available during his or her lifetime only to the Participant. 

ARTICLE 7. DURATION, AMENDMENT AND TERMINATION 

7.1 Duration of the Plan. The Plan shall commence on the date specified herein and shall remain in effect thereafter until terminated
pursuant to Section 7.2. 

  
 5 

 7.2 Amendment, Suspension or Termination. The Board or the Committee may amend, suspend or
terminate the Plan, or any part thereof, at any time and for any reason. No award may be granted during any period of suspension or after termination of the Plan. 

ARTICLE 8. LEGAL CONSTRUCTION 

8.1 Severability. In the event any provision of the Plan shall be held illegal or invalid for any reason, the illegality or invalidity
shall not affect the remaining parts of the Plan, and the Plan shall be construed and enforced as if the illegal or invalid provision had not been included. 

8.2 Requirements of Law. The granting of awards under the Plan shall be subject to all applicable laws, rules and regulations, and to
such approvals by any governmental agencies or national securities markets as may be required. 
 8.3 Governing Law. The Plan and all
awards shall be construed in accordance with and governed by the laws of the State of Delaware, without regard to their conflict-of-law provisions. 

8.4 Captions. Captions are provided herein for convenience only and shall not serve as a basis for interpretation or construction of
the Plan. 

  
 6 

 APPENDIX A 

PERFORMANCE METRICS 

The Committee may establish Performance Goals derived from the following metrics: 

 

	•	 	Backlog 

  

	•	 	Bookings (including annual or total contract value bookings) 

  

	•	 	Cash 

  

	•	 	Cash and short-term investments 

  

	•	 	Cash flow return on investment 

  

	•	 	Comparisons with various stock market indices 

  

	•	 	Deferred revenue 

  

	•	 	Earnings or earnings per share (including earnings before taxes, earnings before interest and taxes or earnings before interest, taxes, depreciation and amortization) 

 

	•	 	Expenses or expense reductions 

  

	•	 	Free cash flow or free cash flow per share 

  

	•	 	Gross profits 

  

	•	 	Headcount 

  

	•	 	Implementation, completion or attainment of measurable objectives with respect to research, development, products, regulatory approvals, projects or recruiting and maintaining personnel 

 

	•	 	Market share 

  

	•	 	Net income (before or after taxes) 

  

	•	 	Operating margin or cash margin 

  

	•	 	Operating profit/loss (on a GAAP or non-GAAP basis) 

  

	•	 	Pre- or after-tax income (before or after allocation of corporate overhead and bonus) 

  

	•	 	Reductions in costs 

  

	•	 	Return on equity 

  

	•	 	Revenue 

  

	•	 	Stock price 

  

	•	 	Total expenses 

  

	•	 	Total stockholder return 

  

	•	 	Working capital 

  

	•	 	Increases or growth in any of the foregoing 

  
 7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00248-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00248-of-00352.parquet"}]]